SGIOF
Shionogi & Co., Ltd.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
18.91
■ 0.00 (0.00%)
MARKET · —
Price
Open
18.91
Prev close
18.91
Day high
16.96
Day low
16.96
Volume
28
Market cap
$16.09B
P/E (TTM)
12.44
52W range
14.25 – 26.00
Trailing performance
Returnvs SPY
1W
+5.63%
+7.0%
1M
+7.74%
+4.0%
3M
+6.95%
+3.8%
6M
-18.16%
-29.2%
YTD
+24.31%
+12.0%
1Y
-0.48%
-20.5%
3Y
+32.30%
-41.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$16.09B
Enterprise value$401.81B
Revenue (TTM)$563.21B
Gross profit$462.28B
EBITDA$150.74B
Net income$263.50B
EPS (TTM)$1.52
Free cash flow$-5.31B
Total cash$298.94B
Total debt$684.13B
Book value / share$13.16
Shares outstanding851.18M
Float850.63M
Short % of float—
Dividend yield2.56%
Beta (5Y)0.03
Valuation & profitability ratios
Trailing P/E12.44
Forward P/E15.25
PEG ratio—
Price / sales—
Price / book1.44
EV / revenue0.71
EV / EBITDA2.67
Gross margin82.08%
Operating margin11.42%
Profit margin46.79%
Return on equity16.77%
Return on assets3.22%
Debt / equity38.59
Current ratio1.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $388.50B | $438.27B | $345.76B | $426.68B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $205.20B | $86.93B | $253.06B | $107.37B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $205.20B | $86.93B | $253.06B | $107.37B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $173.93B | +53.7% |
| Next quarter | — | — | $189.44B | +28.3% |
| Current year | — | — | $702.65B | +80.9% |
| Next year | — | — | $735.22B | +4.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders4.83%
Held by institutions58.77%
Institutions holding362
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
41.14M
Total on file
Moving averages & technicals
SMA 10
18.20
+3.88% from price
SMA 20
17.83
+6.07% from price
SMA 50
17.88
+5.74% from price
SMA 100
18.45
+2.47% from price
SMA 200
18.75
+0.86% from price
EMA 12
18.22
+3.78% from price
EMA 26
17.98
+5.18% from price
EMA 50
18.01
+5.00% from price
RSI (14)
85.8
Overbought
MACD (12,26,9)
0.24
Hist 0.16
ATR (14)
0.14
0.76% of price
Realised vol 30D
17.8%
Annualised
Bollinger upper
18.82
20, 2σ
Bollinger lower
16.83
20, 2σ
50 / 200 cross
Death
17.88 vs 18.75
Trend bias
Above 200
+0.86%
Risk profile
Beta vs SPY
0.02
Less volatile than market
Correlation to SPY
0.00
Largely independent
Realised vol 30D
17.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-38.5%
Peak to trough
Max drawdown 5Y
-73.2%
Peak to trough
ATR 14
0.14
0.76% of price
Beta (reported)
0.03
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Zacks · 19d ago
Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS
Business Wire · 23d ago
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Business Wire · 24d ago
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Zacks · 31d ago
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026
Business Wire · 33d ago
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
Zacks · 33d ago
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
Business Wire · 37d ago
Apnimed Files for US IPO to Support Sleep Apnea Drug Commercialization
MT Newswires · 43d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.